Description
Kin-2787 is under investigation for the treatment of colorectal cancer with specific genetic mutations. Its efficacy and safety are currently being evaluated in clinical trials; it has not yet been approved by regulatory agencies for use in CCR patients.
Mechanism of Action
Kin-2787 is an investigational agent that targets the MAPK pathway, which is often dysregulated in colorectal cancer due to mutations such as KRAS and BRAF.
Side Effects
Fatigue; nausea; diarrhea; neutropenia; thrombocytopenia
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT04913285
Phase 1
Active, not recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
United States, Australia, China, France, Italy, Spain, Taiwan
Quick Info
| Category | Other Medications |
 EMA Status | Experimental |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.